Phase II
Amicus announced that it is halting its CLN6 Batten disease gene therapy program after studies failed to achieve consistent results.
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
The 2022 virtual J.P. Morgan Healthcare Conference got off to a roaring start Monday with deal announcements and plans to drive biopharma companies through the coming year.
Allogene announced that the chromosomal abnormality was not detected in any manufactured AlloCAR T product or any patient treated with the same lot of drugs.
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.
Long-term, opportunities may include using the platform as a vehicle for combination therapies from assets developed by multiple companies.
Sangamo Therapeutics announced that Sanofi US was returning its rights to SAR445136 as it shifts its approach from personalized cell therapies to allogeneic off-the-shelf genomic approaches.
GeneTx Biotherapeutics and Ultragenyx Pharmaceutical’s jointly prepared treatment for Angelman syndrome have been provided a green single by DSMB recently.
The NASH trial achieved the primary endpoint of proton density fat fraction and the secondary endpoint of cT1.
An improvement in cUHDRS was observed in more than half of all evaluable patients and was specifically seen in 75% of the evaluable population who showed excess complement activity at baseline.
PRESS RELEASES